Details for Patent: 8,722,619
✉ Email this page to a colleague
Which drugs does patent 8,722,619 protect, and when does it expire?
Patent 8,722,619 protects REZZAYO and is included in one NDA.
This patent has twenty-five patent family members in sixteen countries.
Drugs Protected by US Patent 8,722,619
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
